Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

European Journal of Neurology

Volumn 16, Issue 3, 2009, Pages 424-426

  Putzki, N ^a,b,c   Kollia, K ^b   Woods, S ^b   Igwe, E ^b   Diener, H C ^b   Limmroth, V ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Glatiramer acetate; Interferon beta; Multiple sclerosis; Natalizumab; Treatment failure

Indexed keywords

BETA INTERFERON; GADOLINIUM; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; HEADACHE; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; THERAPY EFFECT; TREATMENT RESPONSE; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; BRAIN; DISEASE PROGRESSION; FEMALE; GADOLINIUM; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; PEPTIDES; PILOT PROJECTS; RECURRENCE; TREATMENT OUTCOME;

EID: 60049090180     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02519.x     Document Type: Article

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2006 354 : 899 910.
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006 354 : 911 923.
3. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England Journal of Medicine 2006 354 : 924 933.
4. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 6 : 431 441.
5. Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 2007 68 : 1524 1528.
6. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. European Journal of Neurology 2006 13 : 471 474.
7. Zwibel Hl. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurologica Scandinavica 2006 113 : 378 386.
8. Carra A, Onaha P, Luetic B, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. European Journal of Neurology 2008 15 : 386 393. doi :.
9. Confavreux C, Vukusic S. Non-specific immunosuppressants in the treatment of multiple sclerosis. Clinical Neurology and Neurosurgery 2004 106 : 263 269.
10. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004 63 (Suppl. 6 S8 S14.